The efficacy of combination therapy using adeno-associated virus-interferon β and trichostatin A in vitro and in a murine model of neuroblastoma

Journal of Pediatric Surgery

Volumn 43, Issue 1, 2008, Pages 177-183

  Hamner, John B ^a,b   Sims, Thomas L ^a,b   Cutshaw, Aaron ^a   Dickson, Paxton V ^a,b   Rosati, Shannon ^a   McGee, Mackenzie ^a   Ng, Catherine Y ^a   Davidoff, Andrew M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Gene therapy; Interferon ; Neuroblastoma; Trichostatin A; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; BETA1A INTERFERON; CYCLIN DEPENDENT KINASE INHIBITOR 1; TRICHOSTATIN A;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GENE THERAPY; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; HYDROXAMIC ACIDS; INTERFERON-BETA; MALE; MICE; MICE, SCID; NEUROBLASTOMA; PROBABILITY; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38149075849     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2007.09.048     Document Type: Article

References (26)

1. Stark G.R., Kerr I.M., Williams B.R., et al. How cells respond to interferons. Annu Rev Biochem 67 (1998) 227-264
2. Belardelli F., Ferrantini M., Proietti E., et al. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13 (2002) 119-134
3. Streck C.J., Dickson P.V., Ng C.Y., et al. Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta. Cancer Gene Ther 13 (2006) 99-106
4. Kirkwood J.M., Richards T., Zarour H.M., et al. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 95 (2002) 1101-1112
5. Tanabe T., Kominsky S.L., Subramaniam P.S., et al. Inhibition of the glioblastoma cell cycle by type I IFNs occurs at both the G1 and S phases and correlates with the upregulation of p21(WAF1/CIP1). J Neurooncol 48 (2000) 225-232
6. Streck C.J., Ng C.Y., Zhang Y., et al. Interferon-medated anti-angiogenic therapy for neuroblastoma. Cancer Lett 228 (2005) 163-170
7. Streck C.J., Dickson P.V., Ng C.Y., et al. Adeno-associated virus vector-mediated systemic delivery of IFN-β combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models. Clin Cancer Res 11 16 (2005) 6020-6029
8. Chen Q., Gong B., Mahmoud-Ahmed A.S., et al. Apo2L/TRAIL and bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 98 (2001) 2183-2192
9. Slaton J.W., Perrotte P., Inoue K., et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5 (1999) 2726-2734
10. Dickson PV, Hamner JB, Sims TL, et al. Continuous delivery of interferon-beta promotes sustained maturation of intratumoral vasculature. Mol Cancer Res [submitted for publication].
11. Dickson P.V., Hamner J.B., Burger R.A., et al. Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-beta and restricts tumor growth in a murine model of disseminated neuroblastoma. J Pediatr Surg 42 (2007) 48-53
12. Dickson P.V., Hagedorn N.L., Hamner J.B., et al. IFN-β-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model. J Pediatr Surg 42 (2007) 160-165
13. Hamner J.B., Dickson P.V., Gaber M.W., et al. Continuous delivery of interferon-β sensitizes human gliomas to ionizing radiation. J Am Coll Surg 3S1 (2006) S80
14. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92 (2000) 1210-1216
15. Secrist J.P., Zhou X., and Richon V.M. HDAC inhibitors for the treatment of cancer. Curr Opin Investig Drugs 4 (2003) 1422-1427
16. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1 (2002) 287-299
17. de Ruijter A.J., Meinsma R.J., Bosma P., et al. Gene expression profiling to the histone deacetylase inhibitor BL1521 in neuroblastoma. Exp Cell Res 309 (2005) 451-467
18. Muhlethaler-Mottet A., Flahaut M., Bourloud K.B., et al. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspase-dependent increase of the pro- to anti-apoptotic proteins ratio. BMC Cancer 6 (2006) 214
19. Kim M.K., and Carroll W.L. Autoregulation of the N-myc gene is operative in neuroblastoma and involves histone deacetylase 2. Cancer 101 9 (2004) 2106-2115
20. Zhang X., Yashiro M., and Hirakawa K. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 16 3 (2006) 563-568
21. WAF1. J Atheroscler Thromb 13 (2006) 183-191
22. Karam J.A., Fan J., Stanfield J., et al. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer 120 (2007) 1795-1802
23. WAF1 and G1 cell cycle arrest. Int J Urol 13 5 (2006) 581-586
24. Gao G.P., Alvira M.R., Wang L., et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99 (2002) 11854-11859
25. Xiao X., Li J., and Samulski R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72 (1998) 2224-2232
26. Davidoff A.M., Ng C.Y., Sleep S., et al. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J Virol Methods 121 (2004) 209-215